| Analysts were expecting Rigel Pharmaceuticals, Inc. (RIGL) [Chart - News - Analysis] to report earnings of $-0.58 for last quarter, but RIGL missed expectations with actual earnings of $-0.70---12 cents below the consensus estimate. If you compare last quarter's earnings to the $-1.03 the company made per share during the same quarter a year ago, you can see that RIGL’s earnings are up this year. Check this out (it's free!): Stocks You Should Be Watching Right Now; How to Make Good Picks
| | | | | |
-
Essential Reading for Traders
-
| | |
| | | | | | | | Also, if you compare RIGL's 0.00% projected earnings-per-share (EPS) growth rate for the next five years with the projected EPS growth rate of 4.77% for the Drug Manufacturers - Major industry as a whole during that same time frame, you can see that analysts expect RIGL to underperform the industry in the future---which is a bad sign for the stock. Drilling down a little deeper into the Drug Manufacturers - Major industry, you can see how analysts believe RIGL will stack up against some of the other stocks in the industry, like Novartis AG (NVS) [Chart - News - Analysis] and Pfizer Inc. (PFE) [Chart - News - Analysis], in the future. Analysts believe NVS's earnings are going to grow at a rate of -1.00% while PFE's earnings are going to grow at a rate of 1.03%. Earnings season can be a volatile time in the stock market. Check out these videos and articles to be better prepared to take advantage of the large price moves that tend to accompany earnings announcements. - Earnings Season is Here - Find Out How to Trade It - Using Options to Trade Earnings - Understanding Stock Analyst Research and Recommendations More...
Keep up with us:
| 
